drug
vutrisiran
Marketedupdated 6mo agoby $ALNY ALNYLAM PHARMACEUTICALS, INC.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying vutrisiran
- phase3TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
- phase3A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- phase3HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- phase3HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 13, 2027
205 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (13)
- Jul 28, 2036compositionUS 10208307
- Jul 28, 2036compositionUS 10683501
- Jul 28, 2036compositionUS 11286486
- Jul 28, 2036compositionUS 12049628
- Aug 14, 2035compositionUS 10612024
- Aug 14, 2035compositionUS 11401517
- Nov 16, 2032compositionUS 10570391
- Nov 16, 2032compositionUS 9399775
- Dec 12, 2029compositionUS 81060223.1y
- Dec 4, 2028compositionUS 108067912.0y
- Dec 4, 2028compositionUS 88289562.0y
- Dec 4, 2028compositionUS 93705812.0y
- Aug 24, 2028compositionUS 101319071.8y
FDA exclusivities (3)
- Jun 13, 2029ODE-212Orphan Drug (7y)2.6y
- Mar 20, 2028I-964Indication (3y)1.3y
- Jun 13, 2027NCENew Chemical Entity (5y)205d
News(10)
- BioSpace 40 Under 40 winners Paull, Zhang let patients with rare disease lead the way at BridgeBioBridgeBio has produced two young leaders on BioSpace’s 2026 40 Under 40 list. Morgan Paull and Christine Zhang attribute their early success to the company’s unique hub-and-spoke model and a drive…biospace · 3d ago
- Deep dive: Cardiovascular calamities and catalystsBioSpace reviews upcoming cardiovascular milestones after a summer of missed targets.biospace · 6d ago
- STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problemAlnylam is heavily dependent on its heart drug Amvuttra for growth — and sales have been slowing.stat · 7d ago
- Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step downThe deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts.biopharma_dive · 13d ago
- Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilienceAstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears surrounding a top drug and investors rewarded Regeneron for a record quarter.biopharma_dive · 17d ago
- BridgeBio gears up for rare muscular dystrophy launch with FDA approval in sightIf approved, BridgeBio Pharma’s BBP-418—which, according to one Jefferies analyst, boasts “pretty darn compelling” data—would be the first therapy for limb-girdle muscular dystrophy. The FDA has an…biospace · 17d ago
- ‘We need to do better,’ Alnylam CEO admits, as uncertainty looms over transthyretin franchiseAlnylam shares dropped by a quarter on Thursday, with analysts suggesting the decline puts the RNAi specialist within range for a takeout.biospace · 20d ago
- Alnylam bulls and bears fight it out after business-shaking guidance cutWhile Alnylam’s recent reduced revenue guidance spooked investors, analysts remain broadly bullish on the biotech’s commercial prospects.biospace · 1mo ago
- 5 biotechs braving the commercial waters with product launchesA growing number of biotechs are entering the market with newly launched medicines, a pattern indicative of “improving capital markets,” according to Jefferies’ Andrew Tsai.biospace · 2mo ago
- ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsyAt a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors while a failed study pressured Alnylam.biopharma_dive · 2mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that